JP2012527407A - ダイナミン環安定剤の使用 - Google Patents

ダイナミン環安定剤の使用 Download PDF

Info

Publication number
JP2012527407A
JP2012527407A JP2012511102A JP2012511102A JP2012527407A JP 2012527407 A JP2012527407 A JP 2012527407A JP 2012511102 A JP2012511102 A JP 2012511102A JP 2012511102 A JP2012511102 A JP 2012511102A JP 2012527407 A JP2012527407 A JP 2012527407A
Authority
JP
Japan
Prior art keywords
dynamin
ring
dynamin ring
stabilizer
actin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012511102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012527407A5 (cg-RX-API-DMAC7.html
Inventor
フィリップ・ジェイ・ロビンソン
サンジャ・セヴァー
Original Assignee
チルドレンズ メディカル リサーチ インスティテュート
ザ ジェネラル ホスピタル コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by チルドレンズ メディカル リサーチ インスティテュート, ザ ジェネラル ホスピタル コーポレイション filed Critical チルドレンズ メディカル リサーチ インスティテュート
Publication of JP2012527407A publication Critical patent/JP2012527407A/ja
Publication of JP2012527407A5 publication Critical patent/JP2012527407A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2012511102A 2009-05-21 2010-05-21 ダイナミン環安定剤の使用 Pending JP2012527407A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18026109P 2009-05-21 2009-05-21
US61/180,261 2009-05-21
PCT/AU2010/000677 WO2010132959A1 (en) 2009-05-21 2010-05-21 Use of dynamin ring stabilizers

Publications (2)

Publication Number Publication Date
JP2012527407A true JP2012527407A (ja) 2012-11-08
JP2012527407A5 JP2012527407A5 (cg-RX-API-DMAC7.html) 2013-11-14

Family

ID=43125677

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012511102A Pending JP2012527407A (ja) 2009-05-21 2010-05-21 ダイナミン環安定剤の使用

Country Status (8)

Country Link
US (1) US8809386B2 (cg-RX-API-DMAC7.html)
EP (1) EP2432465B1 (cg-RX-API-DMAC7.html)
JP (1) JP2012527407A (cg-RX-API-DMAC7.html)
CN (1) CN102481280A (cg-RX-API-DMAC7.html)
AU (1) AU2010251703B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1010941B1 (cg-RX-API-DMAC7.html)
CA (1) CA2762600C (cg-RX-API-DMAC7.html)
WO (1) WO2010132959A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017518312A (ja) * 2014-06-05 2017-07-06 ユニバーシティ・オブ・カンザス マルメリン類似体および癌治療における使用方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2782643A1 (en) * 2011-11-23 2014-10-01 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Androgen receptor ligands
WO2014063205A1 (en) * 2012-10-26 2014-05-01 The University Of Queensland Use of endocytosis inhibitors and antibodies for cancer therapy
CN105510592A (zh) * 2014-09-26 2016-04-20 中国医学科学院基础医学研究所 梗阻性肾病的蛋白标志物
US11028138B2 (en) * 2016-07-02 2021-06-08 Virongy L.L.C. Compositions and methods for using actin-based peptides to modulate cellular bioactivity and cellular susceptibility to intracellular pathogens
CN113801872A (zh) * 2021-10-11 2021-12-17 杭州师范大学 一种精准调控组装制备稳定酶蛋白环的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056435A2 (en) * 2005-11-08 2007-05-18 The General Hospital Corporation Dynamin mediated diseases and associated methods and products
JP2007515399A (ja) * 2003-11-21 2007-06-14 ザ ユニバーシティ オブ ニューキャッスル リサーチ アソシエイツ リミテッド ダイナミン依存エンドサイトーシスを阻害する方法および薬剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107736A (en) 1993-11-24 2001-01-11 Yissum Res Dev Co Pharmaceutical composition for the prevention of septic shock and for the treatment of chronic inflammatory diseases
WO2001064880A2 (en) 2000-02-28 2001-09-07 Millennium Pharmaceuticals, Inc. Human dynamin 40322
CN1938013A (zh) * 2003-11-21 2007-03-28 纽卡斯尔大学研究协会有限公司 抑制发动蛋白依赖性的细胞内摄作用的方法和药剂
US9144594B2 (en) 2005-11-08 2015-09-29 University Of Miami Cathepsin L mediated diseases and associated methods and products
WO2009034464A2 (en) 2007-09-12 2009-03-19 Newcastle Innovation Limited Indole related compounds with physiological activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007515399A (ja) * 2003-11-21 2007-06-14 ザ ユニバーシティ オブ ニューキャッスル リサーチ アソシエイツ リミテッド ダイナミン依存エンドサイトーシスを阻害する方法および薬剤
WO2007056435A2 (en) * 2005-11-08 2007-05-18 The General Hospital Corporation Dynamin mediated diseases and associated methods and products

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6014024356; Exp. Cell Res., 1998, Vol.243, No.1, pp.185-198 *
JPN6014024358; Oncogene, 1998, Vol.17, No.17, pp.2195-2209 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017518312A (ja) * 2014-06-05 2017-07-06 ユニバーシティ・オブ・カンザス マルメリン類似体および癌治療における使用方法

Also Published As

Publication number Publication date
EP2432465A1 (en) 2012-03-28
BRPI1010941B1 (pt) 2021-06-22
US20120122968A1 (en) 2012-05-17
AU2010251703A1 (en) 2011-12-08
CA2762600C (en) 2018-05-15
US8809386B2 (en) 2014-08-19
EP2432465B1 (en) 2015-07-22
EP2432465A4 (en) 2013-01-02
CA2762600A1 (en) 2010-11-25
AU2010251703B2 (en) 2015-12-24
WO2010132959A1 (en) 2010-11-25
CN102481280A (zh) 2012-05-30
BRPI1010941A2 (pt) 2019-04-09

Similar Documents

Publication Publication Date Title
US9605042B2 (en) Compositions and methods related to tauopathy
CA2762600C (en) Use of dynamin ring stabilizers
JP2009035549A (ja) 神経変性疾患におけるタンパク質凝集に関する材料および方法
CN105378159A (zh) 调节血清低密度脂蛋白(LDL)水平的前蛋白转化酶枯草杆菌蛋白酶/Kexin 9 型(PCSK9)变构结合配体
JPH11514333A (ja) アミロイドの凝集の調節剤
JP2009531299A (ja) ApoE受容体へのApoEの結合のインヒビターによるアルツハイマー病の処置
WO2005021025A2 (en) MODULATION OF β-CATENIN/TCF ACTIVATED TRANSCRIPTION
Lin et al. TFEB agonist clomiphene citrate activates the autophagy-lysosomal pathway and ameliorates Alzheimer's disease symptoms in mice
KR20240024104A (ko) 형광 프로브
CN109982693A (zh) 细胞异常分化和isr相关疾病的预防和治疗方法
US20150329483A1 (en) Methods and Pharmaceutical Compositions for the Treatment of X-Linked Charcot-Marie-Tooth
US12180251B2 (en) Nucleic acids encoding peptides that block binding of a2d-1 to glutamate receptors for treating diseases and disorders
WO2005049009A1 (en) Methods and agents for inhibiting dynamin-dependent endocytosis
JP2013538558A (ja) Tlr媒介疾患を治療するためのtoll様受容体(tlr)の膜貫通型ドメインに基づくペプチド
JP6931218B2 (ja) 細胞膜の損傷修復促進剤
Vassar β-Secretase inhibition
US6878521B1 (en) Fibril-blocking peptide, a method for preventing fibril formation
WO2024238623A1 (en) Doubly constrained peptides as allosteric inhibitors of leucine rich repeat kinase 2
JP2016516752A (ja) アテローム性動脈硬化症の治療および予防のための環状ペプチドの使用
Eichelbaum et al. MAMMALIAN PEPTIDE TRANSPORTERS AS TARGETS FOR DRUG DELIVERY
Kim The WT1 Interacting Protein: a choreographer of podocyte morphology and transcription
EA046785B1 (ru) Способы лечения транстиретинового амилоидоза с применением ag10
Kullak-Ublick et al. Dietrich Keppler". Jörg König', Yunhai Cui", Anne T. Nies'
Cox Amyloidosis: diseases of misfolded proteins
Gupta Lamin AC mutations and heart: Nuclear envelope damage or disruption of transcription?

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130521

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140912

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141216

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20150603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150603

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150713